Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.320
-0.120 (-2.70%)
At close: Apr 28, 2026, 4:00 PM EDT
4.270
-0.050 (-1.16%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Camp4 Therapeutics stock have an average target of 8.60, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 99.07% from the current stock price of 4.32.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Camp4 Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +62.04% | Apr 14, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | +108.33% | Apr 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $7 | Buy | Initiates | $7 | +62.04% | Oct 2, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +177.78% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
2.64M
from 3.50M
Decreased by -24.47%
Revenue Next Year
3.78M
from 2.64M
Increased by 43.00%
EPS This Year
-0.80
from -2.65
EPS Next Year
-0.82
from -0.80
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.2M | 8.4M | ||||||
| Avg | 2.6M | 3.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 162.7% | 218.7% | ||||||
| Avg | -24.5% | 43.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.67 | -0.68 | ||||||
| Avg | -0.80 | -0.82 | ||||||
| Low | -0.91 | -0.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.